American Guinea Pig: The Vioxx/FDA Failure
American Guinea Pig: The Vioxx/FDA Failure
Published April 6, 2017 | Best in Video
The Vioxx story is one of the most widely
publicized stories about the failure of the FDA to do its job. Back in
May 1999, Vioxx was introduced into the market for the purpose of
treating people with arthritis for their pain without the side-effect of
other drugs which caused bleeding. The problem was that it had an
increased ability to cause clotting which, in turn, caused heart
attacks.
The problem was further compounded by the fact that there was a study shortly after it went on the market that showed that, when comparing Vioxx with another drug that was used for the same type of treatment, Naproxen, that there was four times the incidence of heart attacks with Vioxx versus Naproxen. The problem was that the authors of the publication who were funded by Merck, the drug company, said that the difference was because Naproxen had a protective effect, the drug Vioxx was not actually causing those heart attacks. This proved to be false.
The problem was further compounded by the fact that there was a study shortly after it went on the market that showed that, when comparing Vioxx with another drug that was used for the same type of treatment, Naproxen, that there was four times the incidence of heart attacks with Vioxx versus Naproxen. The problem was that the authors of the publication who were funded by Merck, the drug company, said that the difference was because Naproxen had a protective effect, the drug Vioxx was not actually causing those heart attacks. This proved to be false.
No comments:
Post a Comment